Table 2 Haploidentical hematopoietic stem cell transplantation outcomes.

From: Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Estimate (95% CI)

OS (2 y)

LFS (2 y)

GRFS (2 y)

RI (2 y)

Overall (N = 554)

58.7 (54.3–62.9)

52.5 (48.1–56.7)

41.2 (36.9–45.5)

22.3 (18.8–26)

BM (N = 136)

58.9 (49.7–66.9)

53.9 (44.8–62.1)

45.1 (36.1–53.7)

24.4 (17.2–32.2)

PB (N = 418)

58.7 (53.6–63.4)

52 (46.9–56.9)

39.9 (35–44.8)

21.6 (17.7–25.9)

Estimate (95% CI)

NRM (2 y)

aGVHD >=II (180 d)

aGVHD >=III (180 d)

cGVHD (2 y)

Overall (N = 554)

25.2 (21.6–28.9)

28.8 (25–32.7)

9.8 (7.4–12.5)

31.1 (27.1–35.1)

BM (N = 136)

21.7 (15.1–29.1)

22.2 (15.5–29.6)

6.9 (3.4–12.1)

22.9 (15.9–30.6)

PBSC (N = 418)

26.3 (22.1–30.7)

31 (26.5–35.5)

10.7 (7.9–14)

33.7 (29.1–38.5)

Estimate (95% CI)

Ext cGVHD (2 y)

Poly recovery (30 d)

Poly recovery (42 d)

Poly recovery (60 d)

Overall (N = 554)

10.3 (7.9–13.2)

87 (83.9–89.5)

93 (90.5–94.9)

93.8 (91.4–95.5)

BM (N = 136)

7.6 (3.7–13.4)

83.5 (75.9–88.8)

90.2 (83.7–94.2)

90.2 (83.7–94.2)

PBSC (N = 418)

11.2 (8.3–14.6)

88.1 (84.6–90.9)

93.9 (91.1–95.9)

94.9 (92.2–96.7)

  1. y year, d day, BM bone marrow, PBSC peripheral blood stem cells, NRM non-relapse mortality, RI relapse incidence, LFS leukemia-free survival, OS overall survival, GVHD graft-versus-host disease, aGVHD  acute GVHD, cGVHD chronic GVHD, Ext cGVHD extensive chronic GVHD, GRFS GVHD-free relapse-free survival, Poly-polymorphonuclear.
  2. Unless otherwise stated, results are expressed as frequency (%).
Back to article page